New Medical Innovation: Advanced Methods for Postpartum Uterine Hemostasis
The United States Patent and Trademark Office officially issued a groundbreaking new medical patent, Patent No. 12,616,503, titled “Methods for postpartum uterine hemostasis.” This highly anticipated innovation was awarded to ALC Medical Holdings LLC, an advanced medical technology company located in Spartanburg, South Carolina. Developed by inventor Jennifer Rae West, this methodology introduces a transformative and elegant approach to managing postpartum hemorrhage, which remains a critical and potentially life-threatening obstetric emergency worldwide.
According to official USPTO records, the patent application was filed on September 25, 2024, and formally granted on May 5, 2026. The patented method focuses on a postpartum hemorrhage mitigation device that utilizes a specialized suction line and anchoring mechanism to rapidly induce uterine contraction and achieve hemostasis. By establishing a safe, highly controlled negative-pressure environment within the uterine cavity, this medical procedure provides a superior alternative to traditional treatments, significantly improving patient safety and recovery timelines during childbirth.
Why This Invention Is So Innovative
The true clinical innovation behind Patent No. 12,616,503 lies in its uniquely engineered dual-route procedure, which solves a long-standing challenge in postpartum hemorrhage (PPH) management during cesarean deliveries. Traditional vacuum-induced uterine hemostasis devices can be awkward to position or present significant extraction difficulties, sometimes requiring secondary surgical interventions. This method introduces a streamlined workflow: the suction line of the PPH mitigation device is inserted directly through a cesarean incision into the uterine cavity, and then guided downward through the cervix and into the vagina. An anchoring mechanism is carefully positioned adjacent to the internal cervical os to maintain a reliable, hermetic seal.
Once the negative pressure source is activated, it rapidly counteracts uterine atony by promoting uniform muscle contraction and physiological closure of exposed uterine arterioles. Crucially, upon completion of the treatment period, the negative pressure source is disconnected, and the entire assembly, including the suction line and anchoring mechanism, is extracted transvaginally through the cervical canal and vagina. This completely avoids the need to reopen a healing surgical incision or perform an invasive secondary abdominal procedure, lowering the risk of infection, minimizing patient trauma, and accelerating postpartum recovery.
South Carolina Patent of the Month for June 2026
Following its formal issuance in May, this patent has officially been named South Carolina’s Patent of the Month for June 2026. This prestigious recognition highlights the state’s expanding footprint in the life sciences and biomedical innovation sectors, particularly within the Upstate region. Developed in Spartanburg by Jennifer Rae West and backed by ALC Medical Holdings LLC, the technology addresses a paramount priority in global maternal health. Postpartum hemorrhage remains a leading driver of maternal mortality, and this invention provides obstetricians with a highly practical, reliable tool to manage it during surgical births. By awarding it the Patent of the Month for June 2026, the state celebrates a local breakthrough that stands to elevate standard-of-care practices across the United States and validates South Carolina as a competitive hub for medical device innovation and intellectual property development.
U.S. R&D Tax Credit Application and Eligibility
The practical application and technical development of the technology described in this patent are highly eligible for the U.S. Research and Development (R&D) Tax Credit under Internal Revenue Code Section 41. To qualify, the development activities must satisfy the statutory four-part test. First, the project must possess a qualified purpose, which ALC Medical Holdings LLC achieves by designing a novel medical device and clinical method to mitigate postpartum hemorrhage. Second, the development process must eliminate technological uncertainty regarding the structural layout of the flexible suction line, the reliable placement of the anchoring mechanism at the internal cervical os, and the maintenance of a consistent vacuum seal without damaging fragile tissue. Third, the company must engage in a process of experimentation, which involves iterative prototyping, computer-aided mechanical simulations, and rigorous clinical evaluations to refine the device’s dual-route deployment and transvaginal extraction features. Fourth, the work must be technological in nature, relying directly on principles of mechanical engineering, biomaterials, and medical science. Consequently, qualified expenditures, including the wages of design engineers and clinical researchers, prototyping supplies, and contract testing fees, can be leveraged to secure valuable tax credits that offset federal tax liabilities.
